Pharmamel
Drug Discovery
Melatonin at the service of biotechnology, development, and scientific innovation.
Discover investment opportunities through our capital rounds.
Biotechnology R&D&i
Pharmamel Drug Discovery, is established as a line of work within Pharmamel S.L., a biotechnology R&D&i company whose mission is to develop and market innovative drugs based on melatonin and its high antioxidant and anti-inflammatory capacity for application in diseases involving inflammation, oxidative stress, and mitochondrial damage.
Among these diseases is sepsis, an exaggerated response of the body’s immune system to infection caused by bacteria and viruses.
Pharmamel Drug Discovery, with a vision focused on expanding its therapeutic reach, continues to explore new applications of melatonin in various medical conditions.
Current research focuses on deepening the understanding of how melatonin can be used to improve treatments for diseases where oxidative stress and inflammation are key factors.
This approach translates into research aimed at finding innovative solutions that can offer better health outcomes for patients, always maintaining a firm commitment to high-quality science and constant innovation.
Patents
Our patents have gained recognition in the academic field and in the pharmaceutical sector, ensuring the exclusivity of our advanced therapeutic innovations.
This recognition not only strengthens our position in the market but also fosters strategic collaborations with leading research and development institutions. Through these partnerships, we aim to expand the reach of our solutions and accelerate the process of bringing new treatments from the lab to the patient, thus committing to the continuous improvement of healthcare globally.